Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

BACKGROUND: Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: McCormack, Francis X., Inoue, Yoshikazu, Moss, Joel, Singer, Lianne G., Strange, Charlie, Nakata, Koh, Barker, Alan F., Chapman, Jeffrey T., Brantly, Mark L., Stocks, James M., Brown, Kevin K., Lynch, Joseph P., Goldberg, Hilary J., Young, Lisa R., Kinder, Brent W., Downey, Gregory P., Sullivan, Eugene J., Colby, Thomas V., McKay, Roy T., Cohen, Marsha M., Korbee, Leslie, Taveira-DaSilva, Angelo M., Lee, Hye-Seung, Krischer, Jeffrey P., Trapnell, Bruce C.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3118601/
https://ncbi.nlm.nih.gov/pubmed/21410393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1100391
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items